" class="no-js "lang="en-US"> William (Wei) Cao - Medtech Alert
Tuesday, August 12, 2025
William (Wei) Cao

William (Wei) Cao

About William (Wei) Cao

Dr. Cao, Ph.D. B.M., has served as our Chairman of the Board and CEO since our May 2017 inception. Dr. Cao has over 30 years of research and development experience in the biotechnology industry. Prior to founding our company, Dr. Cao co-founded Cellular Biomedicine Group, Inc. (Nasdaq: CBMG), a Nasdaq-listed company engaged in the development of proprietary cell therapies for the treatment of cancer and degenerative diseases, and served as COO, CEO and director from August 2010 to January 2016. Dr. Cao has extensive research experience in the immune-pharmacology field at Harvard Medical School and Stanford University Medical Center. Dr. Cao holds a Bachelor’s degree in Medicine from Fudan University Medical College in Shanghai, China and a Ph.D. in Pharmacology from The Medical College of Virginia in Richmond, Virginia.

Related Story

Gracell Biotechnologies Appoints Accomplished Clinical Leader Dr. Wendy Li as Chief Medical Officer

August 2 2022

Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated […]

Gracell Biotechnologies Unveils Innovation Center in U.S.

January 13 2022

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated […]

Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors

August 18 2021

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly […]

Gracell Biotechnologies Appoints Dr. Yajin Ni as CTO

May 12 2021

Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly […]